Top Story

FDA panel recommends label changes for Nesina

April 16, 2015

An FDA advisory panel recommended label changes for the diabetes drug Nesina after results from a cardiovascular outcomes trial revealed an increased risk for heart disease.

The Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) voted 13-3 Tuesday in favor of including new safety information for Nesina (alogliptin, Takeda Pharmaceuticals). The recommendation follows EMDAC review of the results of the EXAMINE trial, which found an increase in the rate of hospitalization for heart failure in patients who were assigned the drug.

FDA News

FDA panel recommends new safety labeling for Onglyza

April 15, 2015
An FDA advisory panel recommended label changes for the diabetes drug Onglyza after results from a cardiovascular outcomes trial revealed an increased risk for heart…
Meeting News Coverage

Glycemic control may improve clopidogrel response in patients with stable CAD

April 10, 2015
SAN DIEGO — In patients with stable CAD, high levels of plasma glucose reduced clopidogrel efficacy, according to data presented at the American College of…
In the Journals

CABG may confer improved survival over PCI in patients with diabetes

April 8, 2015
Among patients with diabetes with CVD in the Coronary Artery Revascularization Evaluation registry, CABG was associated with better long-term survival and reduced risk…
CME
Debating the Differences and Nuances of Antiplatelet Therapy in ACS and PCI: Not a One-Size-Fits-All?

Debating the Differences and Nuances of Antiplatelet Therapy in ACS and PCI: Not a One-Size-Fits-All?

This activity is supported by an educational grant from Daiichi Sankyo, Inc. and Lilly USA, LLC.

More »
Meeting News Coverage Video
thumbnail for video 3857626096001

Francesco Rubino, MD: 'Converting' bariatric surgery into a diabetes intervention poses challenges

October 24, 2014
BOSTON — Converting a procedure that has been used for years as a weight-loss intervention into a treatment aimed…
More »
CME
Obesity Consults: Volume 2, Number 4 Obesity and the Cardiovascular System

Obesity Consults: Volume 2, Number 4
Obesity and the Cardiovascular System

This activity is supported by an educational grant from Eisai, Inc. and Vivus, Inc.

Obesity is associated with a wide range of comorbid conditions, including diabetes, hypertension, sleep apnea, and…
More »
In the JournalsPerspective

'Bundled' management reduced diabetes-related vascular complications

July 3, 2014
A team-based model with an all-or-none or “bundled” approach to primary care reduced the risk for myocardial infarction, stroke and…
In the Journals

Sitagliptin may increase hospitalizations in patients with diabetes, HF

July 2, 2014
Recent study results found that sitagliptin use by patients with type 2 diabetes and HF may increase the risk for HF-related…
In the Journals

CV risk control differs by sex for patients with type 2 diabetes

July 2, 2014
Composite control of cardiovascular risk factors varies by sex for patients with type 2 diabetes, with women’s significantly lower than…
Meeting News Coverage

RYGB adds CV, quality-of-life benefits for obesity, type 2 diabetes

July 1, 2014
CHICAGO — Roux-en-Y gastric bypass surgery could bring additional benefits for some patients with obesity and type 2 diabetes, according to…
In the Journals

Homeless men boosted health playing pick-up soccer

June 29, 2014
As World Cup competition continues, a timely study published in the Scandinavian Journal of Medicine & Science in Sports showed that playing…
In the Journals

CABG, newer-generation DES yielded similar mortality rates in patients with diabetes

June 26, 2014
Comparable mortality rates were reported for patients with diabetes treated with CABG or PCI using a cobalt-chromium everolimus-eluting…
FDA News

FDA: No clear link between olmesartan, CV risk among patients with diabetes

June 24, 2014
The FDA today announced that a safety review of olmesartan indicates no increased risk for CV events among patients with diabetes.According to a…
Meeting News CoveragePerspective

Empagliflozin reduced BP for patients with type 2 diabetes, hypertension

June 23, 2014
CHICAGO — In patients with type 2 diabetes and hypertension, empagliflozin significantly reduced BP in addition to improving blood glucose…
Meeting News Coverage

More than 10% of patients with acute MI may have undiagnosed diabetes

June 16, 2014
It is estimated that about 10% of patients with MI may also have undiagnosed diabetes, according to new research presented at the American Heart…
Meeting News Coverage

OGTT after MI reveals high undiagnosed diabetes, subsequent high mortality

June 14, 2014
SAN FRANCISCO — New research looking at oral glucose tolerance testing 4 days after both ST-elevation myocardial infarction and non-ST-elevated…
More Headlines »
morganatic-roan
morganatic-roan